Creo Medical (CREO) , a medical device company focused on minimally invasive surgical endoscopy, updated markets on the Royal Oldham Hospital's uptake of its technology, which has now treated over 40 patients using Speedboat Inject, a record time for any NHS hospital to reach the target.
Speedboat Inject is an endoscopy tool that allows endoscopists to remove complex high-risk lesions and even early cancer without the patient requiring invasive surgical treatment. The technology could save the NHS up to £10k compared to traditional surgery, alongside a typically far shorter hospital stay, reduction in waiting list times, and significantly lower risk of complications. 23 NHS England healthcare settings have now adopted SSD, with a target base for the Speedboat (SDD) range of products of more than 350 NHS hospitals,
Looking forward, Creo said SSD will become Royal Oldham's treatment of choice for high-risk polyps suspected of containing early cancer. Hundreds of patients every year are expected to benefit from this treatment option.
Craig Gulliford, CEO of Creo Medical said: "Oldham provides a phenomenal model for what's possible when a hospital immediately recognises the potential of the device and implements the right pathways and resource to maximise its impact.
"To know that there are 40 patients in and around Oldham who have already benefited from our technology and the excellent service provided by Dr Khalid and his team is incredibly gratifying, with the knock-on positive effects on waiting lists and hospital resources now well established.
"To hear plans for the further expansion of the service is also excellent news and we look forward to supporting the hospital in every way we can."
View from Vox
Creo Medical’s successful implementation of SDD at Royal Oldham has demonstrated the product's ability to cut costs, waiting times, prevent further health complications, and ultimately improve patient outcomes.
SDD removes bowel cancer lesions, preventing them from developing into anything more sinister. Bowel cancer is the fourth most common cancer in the UK, with almost 43,000 people diagnosed every year in the UK. SDD reduces the chances of recurrence of a lesion from 15% to 1% and potentially provides a cure for lesions containing early cancer without requiring an operation.
Overall, Creo Medical’s success at Royal Oldham reaffirms its status as one of the leading advanced endoscopy services in the country and helps it to move closer to its goal of prevention, early detection, and treatment of bowel cancer.
Follow Creo Medical for more News and Updates: